OpusPoint Partners has been teaming up with individuals, investors, corporations and researchers with a unified mission to help fledgling companies achieve their goals, by providing the world with innovative solutions that will improve both the diagnosis and treatment of diseases. This investment into research companies that need the extra cash injection can only bode well for a world awaiting the progress made by these struggling companies to reap the benefits of great medical breakthroughs.

Mr. Michael S. Weiss in conjunction with Dr. Lindsay Rosenwald founded the OpusPoint Partners in 2009 and has steadfastly reaped success after success performing above the goals which would have been predicted. In less than two years, they’ve helped in the financing of over twenty companies, applying basic principles to best practices and processes. This has produced excellent rewards in both worlds of drug researching and business financing.

OpusPoint Partners has a promising future under the guidance of these two men who are both passionate about the world of biotechnology and have jointly founded other biotech companies through the years. With a combined 40 year track record between them in the fields of biotech and life sciences investing, there is no doubt that their experience and expertise would be instrumental in changing the way that the diagnosis and subsequent medical treatment of patients is handled.

Biotech investing is expected to be taken to a new level and OpusPoint Partners and Dr. Lindsay Rosenwald have raised the standards for advising and investing in biotechnical facilities by insisting on a strong set of values which are then reinforced by strong business principles. Investors are then provided with optimal returns with minimized risk, a formula which has already been proven effective by their successes.

Overcoming age-old techniques and procedures in medicine and healthcare will require additional effort but Dr. Rosenwald believes that this can be achieved while remaining within ethical boundaries as long as there is an injection of time, money and dedication.

The temptation to ignore ethics in exchange for greater profits has to be resisted if the founding principle of OpusPoint Partners is to be maintained. This principle is built on strong business connections with both the biotechnology and investment communities, thereby establishing a strong and successful conglomeration of partners that remain committed to honesty and integrity within the world of life science and healthcare.

The key to continued achievements in this area is the practice of integrity which has been stamped by honest investing and full open disclosure. True strength comes when companies and industry leaders have established strong relationships sharing the same values that understand that integrity is an inbuilt part of every organization’s culture and not just a good business practice. The world has become more competitive and business leaders are facing temptations of using less than ethical tactics in order to provide positive outcomes from their clinical trials to force an improvement in their earnings and profits.

OpusPoint Partners has proven that it is firmly committed to its shareholders made up of investors and employees and being different by remaining fair in all of its dealings especially when it comes to the investigating, testing and manufacture of drugs.

Dr. Lindsay Rosenwald is no stranger to merging biotechnology with financial investing. On July 10, 2009, Johnson and Johnson acquired a company called Cougar Biotech Labs for approximately one billion dollars which Dr. Rosenwald had founded under the name Cougar Biotechnology Inc. This Los Angeles based company performs research on experimental cancer drugs and has captured the interest of researchers and investors with some impressive experimental drugs that show promise. The company has already achieved success with one of these drugs which has shown great results in the treatment of latter staged prostate cancer.

Dr. Rosenwald has more than 17 years of experience as a biotechnology entrepreneur on Wall Street he has actively founded and recapitalized both private and public companies that are focused on biotechnology and life sciences. His B. S. in Finance from Pennsylvania State University and M. D. from the Temple University School of Medicine was very useful in his management of the Aries Funds (1994 to 2000) and the Orion Fund (2002-2006). The Aries fund has applied more than $1 Billion on healthcare investments while the Orion Fund has dedicated itself to private biotechnology investing in projects like PIPEs.

Dr. Lindsay Rosenwald has formed close connections to the biotechnology-finance industry leaders and is currently a member of the Board of Directors at the Republican Jewish coalition. OpusPoint Partners has geared up to prepare for the advances in healthcare and life science. Additional time and money will be invested in order to be the leaders in the latest innovations that are expected to revolutionize how healthcare is delivered. Their vision is to see a world improved by their collective input into healthcare and medicine, knowing that the future of mankind is stronger and healthier.